Efficient generation and reversion of chromosomal translocations using CRISPR/Cas technology

Area of Science:

• Molecular Biology
• Cancer Research
• Genomics

Background:

• Chromosomal translocations are key drivers of cancer, leading to the formation of fusion oncogenes.
• Understanding tumorigenesis requires robust model cell lines that accurately represent these genetic alterations.

Purpose of the Study:

• To develop a precise method for engineering cell lines with specific chromosomal translocations.
• To create novel cancer models for investigating the mechanisms of tumorigenesis.

Main Methods:

• Utilized the CRISPR/Cas system for targeted genetic engineering.
• Co-applied two guide RNAs to induce specific double-strand breaks, generating chromosomal translocations de novo (e.g., CD74-ROS1).
• Developed a screening method using PCR to identify and isolate cell clones with desired fusion events, including reversion of existing translocations (e.g., BCR-ABL1).

Main Results:

• Successfully generated cell lines with specific chromosomal translocations (CD74-ROS1 and BCR-ABL1) in a predictable manner.
• The CRISPR/Cas-mediated engineering approach proved efficient in creating fusion oncogene models.
• Analysis confirmed that the engineered clones exhibited no unintended genetic alterations, demonstrating the precision of the method.

Conclusions:

• The CRISPR/Cas-based approach is a robust and precise tool for engineering chromosomal translocations in cell lines.
• This method provides reliable and predictable generation of cancer models harboring specific fusion oncogenes.
• The engineered cell lines are suitable for in-depth studies of tumorigenesis and cancer mechanisms.